TG테라퓨틱스사 (TGTX)

Shares of Tg Therapeutics Pharmaceuticals (TGTX) dropped by 7.97% from $7.78 to $7.16 in the trading on Monday, October 9, 2023. The reason why TGTX stock down is due to the outcome of a clinical trial. The primary endpoint of the trial was progression-free survival (PFS), which measures the duration that patients live without their cancer progressing. Unfortunately, Umbralisib, a drug being tested in the trial, did not meet the PFS endpoint. However, there were some positive signs of activity observed, including a reduction in tumor size.

TG Therapeutics (TGTX) fell 7.97% to $ 10.39 on Friday after Cantor Fitzgerald said that September sales for the company's multiple sclerosis (MS) therapy Briumvi needed to be strong to meet consensus estimates.

https://seekingalpha.com/news/4010268-tg-therapeutics-stock-falls-cantor-tracks-briumvi-sales

Shares of TG Therapeutics (TGTX) were crashing 49.3% lower to $10.49 on Tuesday after the company announced its second-quarter results. Total net product revenue was $16 million in the second quarter, all generated by multiple sclerosis (MS) drug Briumvi. But the MS drug's sales were well below the analysts' consensus estimate of nearly $17.5 million.

https://www.fool.com/investing/2023/08/01/why-tg-therapeutics-stock-is-crashing-today/

TGTX's stock fell 14.57% because their rival Roche (RHHBY) unveiled positive result about one-hour infusion for multiple sclerosis patients. Swiss pharma Roche tested an under-the-skin injection of its blockbuster multiple sclerosis treatment, Ocrevus. The news sent TG Therapeutics stock to its lowest point since April.

https://www.investors.com/news/technology/tgtx-stock-how-roche-just-cut-tg-multiple-sclerosis-drug-down-a-peg/